Literature DB >> 16920359

Raised troponin T in inclusion body myositis is common and serum levels are persistent over time.

C Lindberg1, L Klintberg, A Oldfors.   

Abstract

Cardiac Troponin T (cTnT), creatine kinase (CK) and creatine kinase isoenzyme MB (CKMB) were measured in 42 consecutive patients with sporadic inclusion body myositis (s-IBM). 26 patients (62%) had a cTnT level >0.05 microg/L, the cut off used in the diagnosis of myocardial infarction. The cTnT levels correlated somewhat more closely to CKMB (rho=0.83, p<0.0001) than to CK (rho=0.60, p<0.0001). Patients on immunosuppressive treatment had lower cTnT levels than untreated, while there were no significant differences according to age, disease duration or gender. Repeated samples in 26 patients showed that the cTnT levels were essentially unchanged over time up to 17 months. None of the patients had signs of myocardial damage or renal failure at time of sampling. It may be of value to analyse cTnT at some occasion(s) in s-IBM patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920359     DOI: 10.1016/j.nmd.2006.06.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

Review 1.  Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity.

Authors:  Michael Hughes; James B Lilleker; Ariane L Herrick; Hector Chinoy
Journal:  Ann Rheum Dis       Date:  2015-03-02       Impact factor: 19.103

2.  Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.

Authors:  Ulrika Lindgren; Rille Pullerits; Christopher Lindberg; Anders Oldfors
Journal:  Ann Neurol       Date:  2022-06-06       Impact factor: 11.274

3.  The heart in sporadic inclusion body myositis: a study in 51 patients.

Authors:  Fieke M Cox; Victoria Delgado; Jan J Verschuuren; Bart E Ballieux; Jeroen J Bax; Axel R Wintzen; Umesh A Badrising
Journal:  J Neurol       Date:  2009-10-08       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.